• Explore /
  • Poster
  • / Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with squamous cell carcinoma of the anal canal.

Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with squamous cell carcinoma of the anal canal.

Abstract Poster

Authors

null

Suilane Coelho Ribeiro

Instituto do Cancer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil

Suilane Coelho Ribeiro , Camila Motta Venchiarutti Moniz , Rachel Riechelmann , Giovanni Mendonca Bariani , Maria Ignez Braghiroli , Caio Nahas , Renata Coudry , Alexandra Khichfy Alex , Allyne Q. Carneiro , Daniela R. Nebuloni , Joao Glasberg , Paulo Hoff

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon and Rectum

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Citation

J Clin Oncol 32, 2014 (suppl 3; abstr 560)

DOI

10.1200/jco.2014.32.3_suppl.560

Abstract #

560

Poster Bd #

D9

Abstract Disclosures

Similar Posters

Poster

2017 Gastrointestinal Cancers Symposium

Comparison of 5-FU versus capecitabine in combination with mitomycin or cisplatin in the treatment of anal cancer.

Comparison of 5-FU versus capecitabine in combination with mitomycin or cisplatin in the treatment of anal cancer.

First Author: Irene S. Yu

First Author: Stefano Kim

First Author: Marcia Hall

First Author: Antoine Adenis